Physician profile
John Khuu
NPI 1063639011
$2,663.75
in general payments reported to CMS, 2019-2025
39 companies · $213 in 2025
The $213 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,069 · 2020: $1,164 · 2021: $168 · 2022: $32.83 · 2023: $16.41 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $229.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $291.88 | 2019-2023 | Prolia, Evenity |
| Merck Sharp & Dohme LLC | $271.91 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $239.58 | 2019-2021 | |
| Janssen Biotech, INC. | $171.12 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $149.87 | 2019-2020 | |
| Novo Nordisk INC | $123.48 | 2025 | Wegovy |
| Seagen INC. | $116.55 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $108.46 | 2019-2020 | |
| Celgene Corporation | $96.66 | 2019-2025 | Reblozyl |
| Incyte Corporation | $87.03 | 2019-2021 | |
| Pharmacyclics LLC, An Abbvie Company | $70.99 | 2019-2020 | |
| Pfizer INC. | $69.38 | 2019-2020 | |
| Tersera Therapeutics LLC | $69.35 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.45 | 2019-2020 | |
| Lilly USA, LLC | $46.27 | 2019-2020 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $45.96 | 2020 | |
| Kite Pharma, INC. | $45.24 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.63 | 2019-2025 | |
| Beigene USA, INC. | $42.17 | 2020-2021 | |
| Caris Mpi, INC. | $41.93 | 2025 | Mi Cancer Seek |
| Puma Biotechnology, INC. | $40.63 | 2019-2020 | |
| Daiichi Sankyo INC. | $39.64 | 2020-2021 | |
| Eisai INC. | $35.79 | 2019-2020 | |
| Genzyme Corporation | $35.17 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $32.83 | 2022 | |
| Foundation Medicine, INC. | $32.69 | 2019-2020 | |
| Emd Serono, INC. | $29.13 | 2020 | |
| Glaxosmithkline, LLC. | $28.54 | 2020 | |
| Abbvie INC. | $23.09 | 2019 | |
| Genentech USA, INC. | $22.12 | 2019 | |
| Astellas Pharma US INC | $21.97 | 2019 | |
| Epizyme, INC. | $21.67 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.82 | 2019 | |
| Blueprint Medicines Corporation | $19.38 | 2020 | |
| Agios Pharmaceuticals, INC. | $17.01 | 2020 | |
| Eusa Pharma (US) LLC | $16.90 | 2019 | |
| Rigel Pharmaceuticals, INC. | $14.46 | 2019 | |
| Exelixis INC. | $12.59 | 2019 | |
| Taiho Oncology, INC. | $12.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Khuu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.